ELFABRIO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELFABRIO (ELFABRIO).
Recombinant human α-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal α-galactosyl groups, thereby reducing accumulation in tissues.
| Metabolism | Degraded via peptide hydrolysis into small peptides and amino acids. |
| Excretion | Primarily eliminated via renal excretion as intact protein; minimal biliary/fecal elimination (<1%). |
| Half-life | Terminal elimination half-life approximately 0.5–1 hour; short half-life necessitates twice-weekly intravenous dosing. |
| Protein binding | Negligible protein binding (<5%); agalsidase beta is a recombinant protein not highly bound to plasma proteins. |
| Volume of Distribution | Volume of distribution approximately 0.2–0.3 L/kg, suggesting limited extravascular distribution and confinement primarily to vascular space. |
| Bioavailability | 100% (intravenous administration); not administered via other routes. |
| Onset of Action | Intravenous: Clinical reduction in plasma globotriaosylceramide (GL-3) levels observed within weeks; symptom improvement may take months. |
| Duration of Action | Duration of pharmacodynamic effect (GL-3 reduction) persists for 2–4 weeks after last dose despite short half-life; sustained with regular dosing every 2 weeks. |
1 mg/kg intravenously over 2 hours every 2 weeks.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for renal impairment. GFR not clinically relevant for dosing. |
| Liver impairment | No dose adjustment required for hepatic impairment. Not studied in Child-Pugh B or C; use with caution in severe impairment. |
| Pediatric use | For patients aged 16 years and older: 1 mg/kg intravenously over 2 hours every 2 weeks. Safety and efficacy not established in children <16 years. |
| Geriatric use | No specific dose adjustment in elderly; clinical studies included limited patients ≥65 years; no differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELFABRIO (ELFABRIO).
| Breastfeeding | Not known whether excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not determined. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Not associated with fetal harm. However, due to potential for hypersensitivity reactions, use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["None known."]
| Precautions | ["Anaphylaxis and severe allergic reactions","Infusion-associated reactions (IARs)","Hypersensitivity reactions including urticaria, angioedema, and hypotension"] |
Loading safety data…
| Monitor for infusion-related reactions. Assess renal function and serum electrolyte levels periodically. |
| Fertility Effects | No known effects on fertility. No human data; animal studies showed no impairment. |